Evaluation of granulocytes reposition and appearance of the adverse effects produced by the stimulating factors of granulocytic colonies
DOI:
https://doi.org/10.19230/jonnpr.1492Keywords:
Stimulants of granulocytes, Musculoskeletal pain, Dyspnea, Gastrointestinal disordersAbstract
Objective: To evaluate the most frequent adverse effects produced by colony stimulating factors available at the University Hospital San Juan de Alicante (filgrastim and pegfilgrastim).
Materials and methods: Observational, retrospective study, developed at the Pharmaceutical Care Unit for External Patients (UFPE) of the Hospital Universitario de San Juan de Alicante, between February 8 and 26, 2016 (inclusive). Variables collected: Sex, age, diagnosis, chemotherapy scheme, start date chemotherapy treatment, stimulating factor and prescribed dose, cycles received, start date treatment with stimulant factor and adverse effects.
Results: Of the 15 patients treated with colony stimulating factor only the 13.3% were being treated with lower doses than the ones according to their weight. In 100% the medication was correctly prescribed. The main chemotherapy regimen where primary prophylaxis was used was AC for breast cancer. The main side effects were musculoskeletal pain, asthenia / fatigue, and gastrointestinal disorders such as constipation and diarrhea.
Conclusions: Preventive use with granulocytic colony stimulating factor has been shown to reduce the risk and duration of neutropenia. The adverse effects obtained are within the normal range for the use of said medicament.
Downloads
References
Carrato A, Rodríguez LP-A, Rodríguez A. Consenso sobre el manejo de factores de crecimiento. Sociedad Española de Oncología Médica. 2006
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colonystimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25:3158-3167.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(28): 3199-212
Ozer et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Am Soc Clin Oncol Growth Factors Expert Planel. J Clin Oncol 2000; 18: 3558-85.
Crawford J, Althaus B, Armitage J, et al. Myeloid Growth Factors. Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network 2005; 3: 540-55.
Segal B, Robert L, Brown E, Casper C, Dubberke E. Prevention and treatment of cancer related infections. NCCN Clinical Practice Guidelines in Oncology. Version 1.2008, 01/16/2008 National Comprehensive Cancer Network. Accessed: 2008 May 17. Disponible en: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Agencia Europea de Medicamentos. Ficha técnica o resumen de las características producto.
Additional Files
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
